HOPA is actively working on behalf of the hematology/oncology pharmacists and patients to maintain quality and safety in cancer care. Following are recent initiatives that HOPA has participated in on the association's behalf:
FDA Releases Final Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.
GOP Leaders Issue Letter Cautioning Agencies Not to Finalize Rules. Of interest to HOPA is the Medicare Part B Rule which is still in flux.
President's Cancer Panel Releases Latest Report, Improving Cancer-Related Outcomes with Connected Health